Jennifer Lospinoso shares how cell and gene therapy access models differ from normal specialty medications, and how the market will adapt in the next five years.
Jennifer Lospinoso
Advertisement
Jennifer Lospinoso is the managing director and consulting lead at Riparian.
Articles by Jennifer Lospinoso
Jennifer Lospinoso explains how cell and gene therapies are reshaping specialty pharmacy commercialization.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Philip Sclafani: Will PBM Reform Actually Lower Net Drug Costs?
2
How GLP-1 Growth and Specialty Drugs Are Driving Cost Pressure
3
Report: GLP-1s, Oncology to Drive Drug Spending Surge in 2027
4
Why Packaging Is Now a Frontline Issue In Pharma Supply Chains
5